Eloralintide for Obesity

This trial aims to understand how a new treatment called eloralintide, a potential drug for obesity, affects the body's processing of oral contraceptives in women who are overweight or have obesity. Participants will stay in a research unit three times, each for about a week, over eight months. This trial might be suitable for those with a stable body weight, a BMI between 27 and 35, and who use non-hormonal birth control methods. As a Phase 1 trial, participants will be among the first to help researchers understand how this new treatment works in people.

Research has shown that eloralintide is generally safe for people. In studies, many participants experienced significant weight loss with this treatment. Some side effects occurred, but they were usually mild. Most participants did not face serious health issues. Earlier research on adults with obesity or who were overweight found that the treatment was well-tolerated. This suggests that eloralintide is likely safe, although individual reactions can differ.¹²³⁴⁵

Eloralintide is unique because it offers a new approach to tackling obesity by being combined with a contraceptive, which is not the norm for current treatments like lifestyle changes, medications such as phentermine, or surgeries like gastric bypass. This combination could potentially address both weight management and hormonal balance in one go. Researchers are excited about Eloralintide because it is administered subcutaneously, which might offer a more consistent delivery method than oral pills, potentially leading to better outcomes in managing obesity.

Research has shown that eloralintide, a new treatment tested in this trial, offers promising results for weight loss in people with obesity. In earlier studies, participants lost up to 11.3% of their body weight in 12 weeks. Another study found that higher doses led to an average weight loss of up to 20% over 48 weeks. This treatment mimics the effects of amylin, a hormone that helps control appetite and food intake. Early evidence suggests that eloralintide could match the effectiveness of some of the best weight-loss treatments available today. Participants in this trial will receive eloralintide combined with an oral contraceptive.⁵⁶⁷⁸⁹